Whanin Pharm (016580) - Total Liabilities

Latest as of December 2025: ₩57.88 Billion KRW ≈ $39.23 Million USD

Based on the latest financial reports, Whanin Pharm (016580) has total liabilities worth ₩57.88 Billion KRW (≈ $39.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Whanin Pharm - Total Liabilities Trend (2009–2025)

This chart illustrates how Whanin Pharm's total liabilities have evolved over time, based on quarterly financial data. See Whanin Pharm current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Whanin Pharm Competitors by Total Liabilities

The table below lists competitors of Whanin Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Spyrosoft Spólka Akcyjna F:2NP	Germany	€89.73 Million
Tillys Inc NYSE:TLYS	USA	$225.62 Million
Daihan Pharmaceutical Co.Ltd KQ:023910	Korea	₩50.75 Billion
Bogota Financial Corp NASDAQ:BSBK	USA	$785.12 Million
Severn Trent PLC LSE:SVT	UK	GBX15.73 Billion
icad inc NASDAQ:ICAD	USA	$8.68 Million
Yi Jinn Industrial Co Ltd TW:1457	Taiwan	NT$8.33 Billion
Chung Lien Transportation Co Ltd TWO:5604	Taiwan	NT$532.26 Million

Liability Composition Analysis (2009–2025)

This chart breaks down Whanin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 016580 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.04	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.14	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.12	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Whanin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Whanin Pharm (2009–2025)

The table below shows the annual total liabilities of Whanin Pharm from 2009 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩57.88 Billion ≈ $39.23 Million	+18.85%
2024-12-31	₩48.70 Billion ≈ $33.01 Million	+13.22%
2023-12-31	₩43.02 Billion ≈ $29.15 Million	+21.36%
2022-12-31	₩35.45 Billion ≈ $24.02 Million	-1.44%
2021-12-31	₩35.96 Billion ≈ $24.37 Million	+9.12%
2020-12-31	₩32.96 Billion ≈ $22.33 Million	+8.33%
2019-12-31	₩30.42 Billion ≈ $20.62 Million	+8.26%
2018-12-31	₩28.10 Billion ≈ $19.04 Million	-11.50%
2017-12-31	₩31.75 Billion ≈ $21.52 Million	+36.22%
2016-12-31	₩23.31 Billion ≈ $15.80 Million	+23.35%
2012-12-31	₩18.90 Billion ≈ $12.81 Million	+16.26%
2011-12-31	₩16.25 Billion ≈ $11.02 Million	+54.67%
2009-12-31	₩10.51 Billion ≈ $7.12 Million	--

About Whanin Pharm

KO:016580 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$106.36 Million

₩156.95 Billion KRW

Market Cap Rank

#19054 Global

#931 in Korea

Share Price

₩10280.00

Change (1 day)

+0.39%

52-Week Range

₩10020.00 - ₩13130.00

All Time High

₩24391.10